147 related articles for article (PubMed ID: 25854294)
61. Impact of disability status on ischemic stroke costs in Canada in the first year.
Mittmann N; Seung SJ; Hill MD; Phillips SJ; Hachinski V; Coté R; Buck BH; Mackey A; Gladstone DJ; Howse DC; Shuaib A; Sharma M
Can J Neurol Sci; 2012 Nov; 39(6):793-800. PubMed ID: 23041400
[TBL] [Abstract][Full Text] [Related]
62. International comparison of stroke cost studies.
Evers SM; Struijs JN; Ament AJ; van Genugten ML; Jager JH; van den Bos GA
Stroke; 2004 May; 35(5):1209-15. PubMed ID: 15073405
[TBL] [Abstract][Full Text] [Related]
63. A systematic review of the effectiveness, cost-effectiveness and barriers to implementation of thrombolytic and neuroprotective therapy for acute ischaemic stroke in the NHS.
Sandercock P; Berge E; Dennis M; Forbes J; Hand P; Kwan J; Lewis S; Lindley R; Neilson A; Thomas B; Wardlaw J
Health Technol Assess; 2002; 6(26):1-112. PubMed ID: 12433319
[No Abstract] [Full Text] [Related]
64. Economic evaluation of the Melbourne Mobile Stroke Unit.
Kim J; Easton D; Zhao H; Coote S; Sookram G; Smith K; Stephenson M; Bernard S; W Parsons M; Yan B; M Desmond P; J Mitchell P; Cv Campbell B; Donnan GA; M Davis S; Cadilhac DA
Int J Stroke; 2021 Jun; 16(4):466-475. PubMed ID: 32536328
[TBL] [Abstract][Full Text] [Related]
65. Real-world costs of ischemic stroke by discharge status.
Mu F; Hurley D; Betts KA; Messali AJ; Paschoalin M; Kelley C; Wu EQ
Curr Med Res Opin; 2017 Feb; 33(2):371-378. PubMed ID: 27826997
[TBL] [Abstract][Full Text] [Related]
66. Cost-effectiveness of a quality improvement project, including simulation-based training, on reducing door-to-needle times in stroke thrombolysis.
Ajmi SC; Kurz MW; Ersdal H; Lindner T; Goyal M; Issenberg SB; Vossius C
BMJ Qual Saf; 2022 Aug; 31(8):569-578. PubMed ID: 34599087
[TBL] [Abstract][Full Text] [Related]
67. The economic burden of stroke in the United Kingdom.
Youman P; Wilson K; Harraf F; Kalra L
Pharmacoeconomics; 2003; 21 Suppl 1():43-50. PubMed ID: 12648034
[TBL] [Abstract][Full Text] [Related]
68. A national economic and clinical model for ischemic stroke care development in Saudi Arabia: A call for change.
Al-Senani F; Al-Johani M; Salawati M; ElSheikh S; AlQahtani M; Muthana J; AlZahrani S; Shore J; Taylor M; Ravest VS; Eggington S; Cuche M; Davies H; Lobotesis K; Saver JL
Int J Stroke; 2019 Oct; 14(8):835-842. PubMed ID: 31122171
[TBL] [Abstract][Full Text] [Related]
69. How to improve access to appropriate therapy and outcome of the acute ischemic stroke: a 24-month survey of a specific pre-hospital planning in Northern Italy.
Camerlingo M; D'Asero S; Perego L; Rovaris C; Tognozzi M; Moschini L; Galbiati G; Pozzi E; Valoti O
Neurol Sci; 2014 Sep; 35(9):1359-63. PubMed ID: 24664230
[TBL] [Abstract][Full Text] [Related]
70. Higher Incidence of Stroke on the Last Day of the Month in Hungary-a Role for Psychosocial Factors and Financial Insecurity?
Folyovich A; Biczó D; Bajnok A; Bessenyei D; Kis I; Gimesi-Országh J; Béres-Molnár AK; Toldi G
J Stroke Cerebrovasc Dis; 2016 May; 25(5):1192-1195. PubMed ID: 26935123
[TBL] [Abstract][Full Text] [Related]
71. The economics of treating stroke as an acute brain attack.
Bogousslavsky J; Paciaroni M
BMC Med; 2009 Sep; 7():51. PubMed ID: 19775424
[TBL] [Abstract][Full Text] [Related]
72. The budget impact of alteplase in the treatment of acute ischemic stroke in Egypt.
Aref H; El Nahas N; Elsisi GH; Shokri H; Roushdy T
Front Neurol; 2023; 14():1220615. PubMed ID: 38020606
[TBL] [Abstract][Full Text] [Related]
73. The economic case for new stroke thrombolytics.
Johnston SC
Stroke; 2010 Oct; 41(10 Suppl):S59-62. PubMed ID: 20876507
[TBL] [Abstract][Full Text] [Related]
74. Stroke treatment economic model (STEM): predicting long-term costs from functional status.
Caro JJ; Huybrechts KF
Stroke; 1999 Dec; 30(12):2574-9. PubMed ID: 10582980
[TBL] [Abstract][Full Text] [Related]
75. Editorial comment--what can models teach us about stroke treatment? Sorting out the missing bits.
Matchar DB
Stroke; 2004 Jun; 35(6):1497-8. PubMed ID: 15166403
[No Abstract] [Full Text] [Related]
76. UK research expenditure on dementia, heart disease, stroke and cancer: are levels of spending related to disease burden?
Luengo-Fernandez R; Leal J; Gray AM
Eur J Neurol; 2012 Jan; 19(1):149-54. PubMed ID: 21951976
[TBL] [Abstract][Full Text] [Related]
77. Costs of stroke using patient-level data: a critical review of the literature.
Luengo-Fernandez R; Gray AM; Rothwell PM
Stroke; 2009 Feb; 40(2):e18-23. PubMed ID: 19109540
[TBL] [Abstract][Full Text] [Related]
78. Costing hospital resources for stroke patients using phase-type models.
Gillespie J; McClean S; Scotney B; Garg L; Barton M; Fullerton K
Health Care Manag Sci; 2011 Sep; 14(3):279-91. PubMed ID: 21695521
[TBL] [Abstract][Full Text] [Related]
79. Economic burden of stroke in a large county in Sweden.
Persson J; Ferraz-Nunes J; Karlberg I
BMC Health Serv Res; 2012 Sep; 12():341. PubMed ID: 23013284
[TBL] [Abstract][Full Text] [Related]
80. Centralising acute stroke care within clinical practice in the Netherlands: lower bounds of the causal impact.
Freriks RD; Mierau JO; Buskens E; Pizzo E; Luijckx GJ; van der Zee DJ; Lahr MMH
BMC Health Serv Res; 2020 Feb; 20(1):103. PubMed ID: 32041670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
